RNA vs SNA · rev $22.6M vs P/E 17, rev $1.33B
Atrium Therapeutics, Inc. Common Stock (RNA) versus Snap-On Inc (SNA) — a side-by-side from cached financials, not a winner call.
Atrium Therapeutics, Inc. Common Stock (RNA) is a biotechnology company listed on NASDAQ.
Snap-On Inc (SNA) is a tools & accessories company listed on US.
Latest reported RNA revenue for 2026-06-30 was $22.6M. Net income was -$36.8M. Revenue was up 15.3% from 2026-03-31 to 2026-06-30. RNA currently screens at market cap $217.5M.
Latest reported SNA revenue for 2026-07-04 was $1.33B. Net income was $260.6M. Revenue was up 2.0% from 2026-04-04 to 2026-07-04. SNA currently screens at market cap $16.82B and trailing P/E 16.8.
RNA currently screens at market cap $217.5M. SNA currently screens at market cap $16.82B and trailing P/E 16.8.
Not investment advice. Open the RNA and SNA stock pages for the full models.
Not investment advice.